Xencor Picks Top Dose For Kidney Cancer Drug After 45.5% Response Rate In Small Cohort
The company plans FDA talks on an accelerated approval path and a head-to-head trial against tivozanib, with cash it expects to last into 2029.
Xencor, a clinical-stage biotech that engineers antibody drugs for cancer and autoimmune disease, chose 400 mcg/kg as the proposed Phase 3 dose of its kidney cancer drug XmAb819 after 45.5% of 11 evaluable patients at that dose had confirmed tumor responses. The company announced the results Sunday at the ESMO cancer congress in Madrid and filed them with the SEC in an 8-K on Monday.
The 400 mcg/kg numbers
As of an October 1, 2026 data cut, the 11 evaluable patients at 400 mcg/kg had five confirmed partial responses (45.5%) and one unconfirmed partial response, for an unconfirmed rate of 55%. Median progression-free survival, the time before the cancer worsens, had not been reached. More than 70% of patients remained on treatment, and the 6-month progression-free survival estimate was 82%.
The cohort is small: the 95% confidence interval on the 45.5% rate runs from 16.8% to 76.6%. Xencor said safety at this dose matched the lower-dose cohorts.
XmAb819 is a bispecific antibody that targets ENPP3 on tumor cells and recruits T cells to kill them. Patients in the study had all received a PD-(L)1 inhibitor and a VEGFR-targeted pill, with a median of three prior lines of therapy.
Lower doses and safety
Of the 68 patients in the three expansion cohorts, response rates were measured in efficacy-evaluable subsets as of a September 1, 2026 data cut. The confirmed rate was 30% at 100 mcg/kg (30 patients) and 44% at 200 mcg/kg (25 patients).
Treatment was stopped over related adverse events in 5.9% of expansion patients, and 72.1% had a related event of Grade 3 or higher. The most common severe events were liver enzyme rises, rash and low blood pressure, mostly early in treatment, according to the company.
Path to a late-stage trial
Xencor plans to discuss a potential accelerated approval pathway with the FDA in the first half of 2027, for patients who have exhausted standard care. In pooled data, patients who had progressed after a PD-(L)1 inhibitor and at least two VEGFR pills (n=42) had a 45% confirmed response rate. The triple-class group that also received a HIF2α inhibitor (n=23) had 35%. Xencor's presentation estimates about 9,200 US patients fit the first group in 2025, based on Komodo Health claims data.
The company also plans a global randomized trial against tivozanib, aiming to start a registration-enabling study by the end of 2027. In a similar subgroup of another trial, tivozanib produced a 10.5% response rate and median progression-free survival of 5.4 months. Xencor cautions that cross-trial comparisons are illustrative only.
CEO Bassil Dahiyat said the company plans to start a potential registration-enabling study next year, and that cash runway into 2029 leaves it "well positioned" to push its oncology and autoimmune work.
Data from at least 20 patients at 400 mcg/kg and from subcutaneous dosing are due in the first half of 2027, alongside the end-of-Phase 1 meeting with the FDA.
Sources
- 8-K Filing — Xencor Inc (XNCR) — SEC EDGAR
- Exhibit ea030959601ex99-1.htm — Xencor Inc 8-K exhibit — SEC EDGAR
- Exhibit ea030959601ex99-2.htm — Xencor Inc 8-K exhibit — SEC EDGAR
- Xencor Shares Gain After Releasing Early-Stage Trial Data for Kidney Cancer Treatment — MarketWatch
- Xencor, Inc. (XNCR) Stock Price, News, Quote & History - Yahoo Finance — Yahoo Finance
- Xencor reports promising kidney cancer drug results, plans late-stage trial (XNCR:NASDAQ) | Seeking Alpha — seekingalpha.com
- Biggest stock movers Monday: XCNR, SGRY, AGEN | Seeking Alpha — seekingalpha.com
- Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors – Company Announcement - FT.com — Financial Times